PDCD1LG2 and neoplasm: Lakins et al. [94] blocked the activity of PD-L2 or FASL using antibodies in mouse tumor models and observed a reduction in tumor volume and enhanced infiltration and restoration of the killing capacity of antigen-specific CD8+ T cells.